Nexodal (Naloxone Hydrochloride)

Naloxone Hydrochloride, the active ingredient in Nexodal, is an opioid antagonist presented as a sterile solution for intramuscular and intravenous use. It rapidly reverses opioid‑induced respiratory depression and is employed in emergency settings for patients experiencing opioid overdose. GNH USA supplies Nexodal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nexodal, an opioid antagonist, is used to counteract the effects of opioid toxicity and respiratory depression. - Opioid overdose: restores normal breathing and consciousness in patients with life‑threatening opioid intoxication. - Opioid‑induced respiratory depression: rapidly reverses suppressed respiration caused by opioid administration. - Accidental opioid exposure: provides immediate antidotal action in cases of unintended opioid ingestion, especially in children.

Naloxone is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea - Vomiting - Sweating - Headache - Agitation - Elevated blood pressure

Serious or Rare Side Effects: - Severe hypertension - Cardiac arrhythmias - Pulmonary edema - Seizures - Anaphylactic reaction - Acute withdrawal syndrome in opioid‑dependent individuals

When using Nexodal, careful clinical assessment and monitoring are essential. - Assess airway and breathing: ensure the patient can maintain airway before administration. - Monitor vital signs: observe blood pressure, heart rate and oxygen saturation after dosing. - Confirm opioid involvement: administer only when opioid overdose is suspected. - Avoid in known hypersensitivity: do not give to patients with documented allergy to naloxone. - Cardiovascular caution: use with caution in patients with pre‑existing heart disease. - Store at room temperature: keep in original packaging, protect from moisture and light.

Naloxone may interact with other medications, influencing its efficacy or safety.

Major Interactions (Avoid): - Mixed agonist‑antagonist opioids (e.g., buprenorphine): can precipitate severe withdrawal. - High‑dose opioid agonists: may require repeated naloxone dosing, reducing effectiveness.

Moderate Interactions (Monitor Closely): - Vasopressors: may need higher naloxone doses to achieve reversal. - Antihypertensive agents: concurrent use can mask hypotensive episodes. - CNS stimulants: may increase risk of agitation or seizures. - MAO inhibitors: monitor for exaggerated cardiovascular responses.